ISSN: 1300-0292
İndekslendiği Dizinler: SCIENCE CITATION INDEX EXPANDED
CINAHL, Index Copernicus,
Chemical Abstracts (CA),
Excerpta Medica / EMBASE
Dil: Türkçe, İngilizce
İçerik: Orijinal Araştırma, Derleme, Editöre Mektup, Olgu Sunumu, Tıp Eğitimi, Tıbbi Kitap İncelemeleri
|
|
|
Treatment In Adult Acute Lymphoblastic Leukemia
E. Naci TİFTİK*, M. Orhan AYYILDIZ**, Abdurrahman IŞIKAKDOĞAN*, Ekrem MÜFTÜOĞLU***
* Yrd.Doç.Dr., Dicle Üniversitesi Tıp Fakültesi İç Hastalıkları, Hematoloji BD,** Doç.Dr., Dicle Üniversitesi Tıp Fakültesi İç Hastalıkları, Hematoloji BD,*** Prof.Dr., Dicle Üniversitesi Tıp Fakültesi İç Hastalıkları, Hematoloji BD, DİYARBAKIR
The outcomes of treatment of adult acute lymphoblastic leukemia (ALL) have been improved with current chemotherapy methods in the past two-three decades. Treatment of ALL now results in complete remission (CR) rates of 80%-90% and long-term survival rates 30%-40%. Mature B cell and T cell ALL cases that previously had a poor prognosis are curable subgroups. Maintenance therapy is a standart component of pediatric ALL, but its benefit is disrupted in adults. Allogeneic stem-cell transplantation (SCT) isn't recommended with the exception of the patients with Philadelphia chromosome-positive (Ph+) or pro-B ALL with t(4,11) in ALL during first remission (CR1). In addition those with B-lineage ALL and initial leukocyte counts > 100.000/mm3 can be cured by allogeneic SCT. Allogeneic SCT should be carried out during second remission (CR2) and in advanced ALL. Autologous SCT isn't recommended for patient with Ph+ ALL and it's ineffective for patients with advanced ALL.Keywords: Acute lymphoblastic leukemia, treatmentTurkiye Klinikleri J Med Sci 2000, 20:245-254
|
|
|
|
|
